SamanTree Medical, a Lausanne, Switzerland-based medical technology company, raised $14M in Series B funding.
The round was led by Relyens Innovation Santé, advised by Turenne Capital, with participation from new investors Mutuelles Impact, Wille Finance, Noshaq and WE Life Sciences (Wallonie Entreprendre), along with returning investors Panakès Partners, BOM and b2venture. In conjunction with this financing round, SamanTree Medical will establish its headquarters and an operational base in Wallonia (Belgium), while the R&D operations will remain in Lausanne, Switzerland.
The company intends to use the funds to further develop and commercialize the Histolog® Scanner, expand its reach in Europe and the United States, and enhance its digital suite.
SamanTree Medical is dedicated to improving outcomes for patients undergoing surgery through medical imaging solutions. The company has developed the Histolog Scanner, a device that offers real-time, high-resolution fresh tissue surface imaging during surgical procedures, that may significantly enhance the accuracy of tissue removal or biopsy. It covers a broad range of surgical applications in surgery and is currently commercialized in Europe.
The new Board composition is as follows:
- Fabrizio Landi
- Claire Poulard
- Henry Charlton
- Dr. Charles Carignan (Chairman)
- Olivier Delporte (CEO)
FinSMEs
16/07/2024